The Nobel Assembly at Sweden's Karolinska Institutet announced Monday that the 2026 Nobel Prize in Physiology or Medicine will be shared by Karl Deisseroth of Stanford University and Peter Hegemann and Georg Nagel, both of German universities, "for their discoveries concerning light-gated ion channels and optogenetics."
Thomas Perlmann, secretary-general of the Nobel Assembly, said the technique the laureates developed "makes it possible to switch on, or off, the activity of individual nerve cells in a living brain," adding that "this method is now being used in laboratories around the world to reveal the brain's mysteries."
From pond algae to brain circuits
Hegemann and Nagel's contribution dates to the early 2000s, when they identified channelrhodopsin, a protein in green algae that opens briefly in response to light, letting charged ions flow across a cell membrane. Around 2005, Deisseroth and colleagues showed that the same protein, delivered into mammalian neurons through gene-delivery techniques, could make those neurons fire — or stay silent — on command, simply by switching a light on or off. The approach, soon named optogenetics, gave neuroscientists a tool they had never had: a way to control specific, genetically defined types of brain cells with millisecond precision, rather than merely observing them.
The technique spread quickly through research labs after 2005 and is now considered one of the most widely adopted tools in modern neuroscience. It has been used to trace the neural circuits involved in movement, sleep, fear, reward and memory in animal models, and has shaped the understanding of conditions including depression, addiction and Parkinson's disease.
Perlmann said all three laureates were "surprised and delighted" when he reached them by phone, and that each independently described the prize as especially meaningful because they were sharing it with close collaborators and friends. Coverage of the announcement noted that the trio has already collected most of the field's major honors over the past decade, including the Lasker Award and the Shaw Prize, both often described as predictors of eventual Nobel recognition.
Optogenetics itself remains primarily a laboratory research tool rather than an approved therapy. Experimental gene-therapy treatments that borrow its light-sensitive proteins to partially restore vision in people with inherited blindness are in early-stage clinical trials, but no optogenetic treatment has yet received full regulatory approval. Scientists say the prize recognizes a methodology that reshaped how an entire field studies the living brain — a more fundamental, if less immediately visible, kind of impact than a new drug or device.
